The prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is highly expressed in the malignant human prostate epithelium. Therefore, PSMA has emerged as a very attractive target for developing radiopharmaceuticals for the diagnosis, e.g., by positron emission tomography (PET) imaging, and radiotherapy of prostate cancer. The aim of this study was to develop F-labeled PSMA ligands bearing different F-glycosyl moieties to study the effect on the clearance behavior of radiotracers in addition to their tumor binding ability. Therefore, we applied click chemistry-based F-fluoroglcosylation using 2-deoxy-2-[F]fluoroglucosyl azide or 6-deoxy-6-[F]fluoroglucosyl azide as prosthetic groups for the radiosynthesis of the F-fluoroglycosylated glutamate-urea-lysine-based PSMA inhibitors 2-[F]FGlc-PSMA ([F]) and 6-[F]FGlc-PSMA ([F]). The PSMA inhibitory potencies were determined by competitive radioligand binding assays using Tc-MIP-1404 and PSMA-expressing PC-3 PIP cells, revealing moderate PSMA inhibitory potencies for [F] (IC = 234 nM) and [F] (IC = 59 nM). Biodistribution and small-animal PET studies were performed using PSMA-positive PC-3 PIP and PSMA-negative PC-3 tumor-bearing nude mice. PSMA inhibitors [F] and [F] were obtained in high radioactivity yields of 19-22% (nondecay-corrected, referred to [F]fluoride) and with molar activities of 71-136 GBq/μmol. In the biodistribution studies, the uptake levels of [F] and [F] in PC-3 PIP tumors were 13 ± 3%ID/g and 6 ± 5%ID/g at 60 min p.i., respectively. PSMA-negative PC-3 tumors and all other tissues had negligible low uptake values. Interestingly, [F] had high uptake in the kidneys, with remarkable retention from 30 to 60 min p.i. (74 to 72%ID/g). In contrast, [F] revealed a low uptake of 7.5%ID/g in the kidneys at 30 min p.i. and was rapidly cleared through the kidney (0.9%ID/g at 120 min p.i.). In direct comparison to a Ga-PSMA-11 PET scan of the same mouse, [F] and [F] showed 2- to 3-fold higher uptake values in PC-3 PIP tumors. Both radiotracers were solely cleared via the kidneys and not via the hepatobiliary pathway. The regional kidney distribution pattern of the tracers in the kidneys revealed that Ga-PSMA-11 and 2-[F]FGlc-PSMA([F]) mainly accumulated in the cortex of the kidneys, whereas 6-[F]FGlc-PSMA([F]) showed a 10-fold lower kidney uptake with accumulation in the inner medulla or pelvis of the kidneys. Overall, the developed 6-fluoroglucosyl derivative [F], with its considerably low kidney uptake and fast clearance, demonstrated high uptake in PSMA-positive tumors This candidate could, therefore, be valuable for translation into the clinic.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.molpharmaceut.9b01179 | DOI Listing |
Eur J Nucl Med Mol Imaging
December 2024
Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland.
Purpose: With the growing interest in exploring radiolanthanides for nuclear medicine applications, the question arises as to whether they are generally interchangeable without affecting a biomolecule's pharmacokinetic properties. The goal of this study was to investigate similarities and differences of four (radio)lanthanides simultaneously applied as complexes of biomolecules or in ionic form.
Methods: Inductively coupled plasma mass spectrometry (ICP-MS) was employed for the simultaneous detection of four lanthanides (Ln = lutetium, terbium, gadolinium and europium) in biological samples.
Cancer Biother Radiopharm
November 2024
Department of Clinical Sciences Lund, Section for Oncology, Lund University, Lund, Sweden.
Prostate-specific membrane antigen (PSMA) is a target for diagnostic positron emission tomography (PET)-tracers and radiopharmaceutical therapy (RPT), for example, [Lu]Lu-PSMA-617, in prostate cancer. This autoradiography study investigates [Lu]Lu-PSMA-617 intratumoral distribution over time, compared with PSMA expression, proliferation (Ki67), and [Ga]Ga-PSMA-11, [F]F-PSMA-1007, [F]-fluorodeoxyglucose, and [F]-fluorocholine distribution. Mice with LNCaP, 22Rv1, or PC-3 PIP xenografts got [Lu]Lu-PSMA-617 i.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
January 2025
Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Prostate
December 2024
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Background: Proliferating cell nuclear antigen (PCNA) is essential for DNA replication and repair, cell growth, and survival. PCNA also enhances androgen receptor (AR) signaling in prostate cancer (PC) cells. We identified a PCNA interaction protein (PIP) box at the N-terminal domain of AR and developed a small peptide PCNA inhibitor R9-AR-PIP containing AR PIP-box.
View Article and Find Full Text PDFNucl Med Biol
September 2024
Molecular Imaging and Theranostics Center, University of Missouri, Columbia, MO, United States of America; Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States of America; Department of Radiology, University of Missouri, Columbia, MO, United States of America.
Background: Prostate cancer affects 1 in 6 men, and it is the second‑leading cause of cancer-related death in American men. Surgery is one of the main treatment modalities for prostate cancer, but it often results in incomplete resection margins or complete resection that leads to nerve damage and undesirable side effects. In the present work, we have developed a new bimodal tracer, NODAGA-sCy7.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!